Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03579524
Other study ID # M336
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2018
Est. completion date September 15, 2019

Study information

Verified date November 2020
Source Fayoum University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Breast cancer is by far the world's most common cancer among women and the most common cause of female death from cancer worldwide. It's worldwide incidence is 43.4 in 100.000 while in Egypt is 48.8 in 100.000. One of the most common surgical procedures for it is modified radical mastectomy (MRM), It is account for 31% of all breast surgery cases. Post-mastectomy pain is a big problem affecting the outcome of surgery. It was used to be managed by opioids which may lead to many side effects such as nausea, vomiting, ileus, over sedation and respiratory depression. Chronic pain syndrome (phantom breast pain, paraesthesias, and intercostobrachial neuralgia) may be developed due to inadequate pain control. So many regional analgesic techniques have been developed for effective pain control. The safest and easiest is local wound infiltration with local anesthesia but the duration of action is limited. Intercostal nerve block and interpleural block are effective, but there is a fear of pneumothorax and transient Horner's syndrome. Thoracic epidural analgesia is not preferred however it's efficacy because of possible neurological and hemodynamic side effects. The gold standard now is thoracic paravertebral block (PVB) which provide effective analgesia with minimal hemodynamic derangement but it carries a risk of pneumothorax in addition to slightly complex technique. Ultrasound-guided interfascial plane blocks such as pectoral nerve (PECS) block type 1 and 2 , serratus anterior plane block (SAPB) and erector spinae plane block (ESP) which is a recent block newly described for various surgeries for postoperative analgesia have also been reported as alternatives, with the advantages of simplicity, ease of performance and fewer complications. there is no sufficient Randomized controlled trails that assess the effectiveness and safety of erector spinae plane block ESPB in controlling post mastectomy pain This study compares the analgesic efficacy of ultrasound-guided erector spinae plane block (ESPB) and serratus anterior plane block (SAPB) in patients undergoing MRM with axillary dissection.


Description:

Preoperative preparation: History taking, physical examination, and investigations will be done according to the local protocol designed to evaluate the patients. This includes complete blood count, blood sugar level, serum urea and creatinine, liver function tests, coagulation profile and electrocardiogram (ECG). Before surgery, the participants will receive education about the VAS pain score (0-100 mm) (where0=no pain and 100 = worst comprehensible pain) and the details of the nerve block procedures. After 6 hours of fasting, the patients will be taken to the operation theatre. Anesthetic management: The patient will receive Midazolam 0.03 mg/kg intravenous (IV), Metoclopramide 10 mg IV, Ranitidine 50 mg IV and Cefotaxime 1 gm as a premedication. Intravenous access will be obtained with an 18-gauge intravenous (IV) cannula in the contralateral upper limb of the surgical site and monitors (pulse oximeter, electrocardiography, non-invasive blood pressure (NIBP) and capnography) will be applied. All patients will receive pre-oxygenation with 100% O2 for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of End Tidal Carbon Dioxide Tension (EtCO2) ≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperatively when either heart rate or Non-Invasive Blood Pressure (NIBP) report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria. A high-frequency ultrasound probe Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810™, USA).and a 22-gauge, 50 mm echogenic needle (Stimuplex D®; B Braun, Germany) will be used for performing the blocks. Patients in group (S) will receive serratus anterior plane block and those in group (E) will receive Erector spinae plane block. Both of these blocks will be performed after induction of general anesthesia by an experienced anesthesiologist (who is well trained in ultrasound-guided regional anesthesia). After proper skin sterilization with povidone-iodine solution. For the ultrasound-guided serratus anterior plane block, the patient will be placed in supine position with the arm abducted. Ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs the linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) .the thoracodorsal artery (slightly posterior) will be used as extra guide in the identification of the plane superficial to the serratus muscle. The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to postero-inferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected. For the ultrasound-guided erector spinae plane block At first the patient will be placed in a lateral decubitus with the operation site up. The vertebrae will be counted from cephalad to caudal direction until we reach T5 spinous process as the first palpable spinous process is C7. Ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle (the needle tip contacts the tip of the transverse process), 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle a total of 20 mL of 0.25% bupivacaine will be injected next. Post-operative care Patients will be transferred to post-anesthetic care unit (PACU) for 2 hrs after anesthesia emergence. The patients will be discharged from the PACU after fulfilling the discharge criteria based on the modified Aldrete score> 9 The patient will receive analgesic according to the local institutional protocol as the following (paracetamol 1gm IV infusion/8 hours, ketorolac 30 mg Intramuscular/12 hours) as 2 components of multimodal anesthesia regimen for postoperative pain control. A postoperative rescue analgesia with morphine sulfate IV per a titration protocol (3 mg IV as a bolus dose which can be repeated every 5 minutes with a maximum dose of 15mg per 4 hours or 45mg per 24 hours) will be employed if visual analog pain scale (VAS) > 4. The morphine titration protocol will be suspended with Oxygen saturation < 95%; Respiratory rate < 10 / min; the development of sedation (Ramsay sedation scale >2); development of acute adverse effects (allergy, marked itching, excessive vomiting, and hypotension with systolic blood pressure less than 20% of baseline values); or attaining adequate level of analgesia.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date September 15, 2019
Est. primary completion date August 15, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - female aged >18 years with breast cancer eligible for modified radical mastectomy. - American Society of Anesthesiologists Physical Status I to IV. Exclusion Criteria: - Patient refusal. - body mass index (BMI) > 40. - local infection at the site of the block. - local anesthetic allergy. - significant neurological or respiratory disease.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Erector Spinae Plane Block
At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
Serratus Anterior Plane Block
At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.

Locations

Country Name City State
Egypt Fayoum University hospital Madinat al Fayyum Faiyum Governorate

Sponsors (1)

Lead Sponsor Collaborator
Fayoum University Hospital

Country where clinical trial is conducted

Egypt, 

References & Publications (8)

Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013 Nov;68(11):1107-13. doi: 10.1111/anae.12344. Epub 2013 Aug 7. — View Citation

Bonvicini D, Giacomazzi A, Pizzirani E. Use of the ultrasound-guided erector spinae plane block in breast surgery. Minerva Anestesiol. 2017 Oct;83(10):1111-1112. doi: 10.23736/S0375-9393.17.12015-8. Epub 2017 May 11. — View Citation

Bonvicini D, Tagliapietra L, Giacomazzi A, Pizzirani E. Bilateral ultrasound-guided erector spinae plane blocks in breast cancer and reconstruction surgery. J Clin Anesth. 2018 Feb;44:3-4. doi: 10.1016/j.jclinane.2017.10.006. Epub 2017 Oct 21. — View Citation

Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451. — View Citation

Gupta K, Srikanth K, Girdhar KK, Chan V. Analgesic efficacy of ultrasound-guided paravertebral block versus serratus plane block for modified radical mastectomy: A randomised, controlled trial. Indian J Anaesth. 2017 May;61(5):381-386. doi: 10.4103/ija.IJA_62_17. — View Citation

Kimachi PP, Martins EG, Peng P, Forero M. The Erector Spinae Plane Block Provides Complete Surgical Anesthesia in Breast Surgery: A Case Report. A A Pract. 2018 Oct 1;11(7):186-188. doi: 10.1213/XAA.0000000000000777. — View Citation

Matsumoto M, Flores EM, Kimachi PP, Gouveia FV, Kuroki MA, Barros ACSD, Sampaio MMC, Andrade FEM, Valverde J, Abrantes EF, Simões CM, Pagano RL, Martinez RCR. Benefits in radical mastectomy protocol: a randomized trial evaluating the use of regional anesthesia. Sci Rep. 2018 May 18;8(1):7815. doi: 10.1038/s41598-018-26273-z. — View Citation

Veiga M, Costa D, Brazão I. Erector spinae plane block for radical mastectomy: A new indication? Rev Esp Anestesiol Reanim. 2018 Feb;65(2):112-115. doi: 10.1016/j.redar.2017.08.004. Epub 2017 Nov 2. English, Spanish. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The duration of analgesia of the two blocks the pain will be assisted based on the time needed for the first dose rescue analgesia. At 48 hours postoperative
Secondary The cumulative opioids (morphine) consumption The total amount of opioids received post operative At 24 hours postoperative
Secondary The cumulative opioids (morphine) consumption The total amount of opioids received post operative At 48 hours postoperative
Secondary The intervals between opioid (morphine) doses the time needed between two successive opioid doses At 24 hours postoperative
Secondary The intervals between opioid (morphine) doses the time needed between two successive opioid doses At 48 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At one hour postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 6 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 12 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 18 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 24 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 30 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 36 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 42 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at rest the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 48 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At one hour postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 6 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 12 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 18 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 24 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 30 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 36 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 42 hours postoperative
Secondary The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain At 48 hours postoperative
Secondary Incidences of complications related to both techniques complications related to the Block or drug administered up to 72 hours postoperative
Secondary Nausea Morphine related side effect At 2 hours postoperative
Secondary Nausea Morphine related side effect At 6 hours postoperative
Secondary Nausea Morphine related side effect At 12 hours postoperative
Secondary Nausea Morphine related side effect At 24 hours postoperative
Secondary Nausea Morphine related side effect At 48 hours postoperative
Secondary Nausea Morphine related side effect At 72 hours postoperative
Secondary Vomiting Morphine related side effect At 2 hours postoperative
Secondary Vomiting Morphine related side effect At 6 hours postoperative
Secondary Vomiting Morphine related side effect At 12 hours postoperative
Secondary Vomiting Morphine related side effect At 24 hours postoperative
Secondary Vomiting Morphine related side effect At 48 hours postoperative
Secondary Vomiting Morphine related side effect At 72 hours postoperative
Secondary Pruritus Morphine related side effect At 2 hours postoperative
Secondary Pruritus Morphine related side effect At 6 hours postoperative
Secondary Pruritus Morphine related side effect At 12 hours postoperative
Secondary Pruritus Morphine related side effect At 24 hours postoperative
Secondary Pruritus Morphine related side effect At 48 hours postoperative
Secondary Pruritus Morphine related side effect At 72 hours postoperative
Secondary Over-sedation Morphine related side effect At 2 hours postoperative
Secondary Over-sedation Morphine related side effect At 6 hours postoperative
Secondary Over-sedation Morphine related side effect At 12 hours postoperative
Secondary Over-sedation Morphine related side effect At 24 hours postoperative
Secondary Over-sedation Morphine related side effect At 48 hours postoperative
Secondary Over-sedation Morphine related side effect At 72 hours postoperative
Secondary Urine retension Morphine related side effect At 2 hours postoperative
Secondary Urine retension Morphine related side effect At 6 hours postoperative
Secondary Urine retension Morphine related side effect At 12 hours postoperative
Secondary Urine retension Morphine related side effect At 24 hours postoperative
Secondary Urine retension Morphine related side effect At 48 hours postoperative
Secondary Urine retension Morphine related side effect At 72 hours postoperative
Secondary The duration of surgery time needed to perform surgery Once at completion of surgery
Secondary Intraoperative fentanyl needed The amount of Fentanyl given intraoperative as fentanyl will be given when either heart rate or NIBP(Non-Invasive Blood Pressure) report an increase by more than 20% of the basal records Once at completion of surgery
Secondary Patients' satisfaction with postoperative analgesia Will be evaluated according to a satisfaction score (poor = 0; fair = 1; good = 2; excellent= 3) after 72 hours postoperative
Secondary Age In years Once the patient is recruited
Secondary weight In kilograms Once the patient is recruited
Secondary Height In meters Once the patient is recruited
Secondary BMI In kilogram per square meter Once the patient is recruited
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2